Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
May 06, 2024 08:00 ET
|
PROCEPT BioRobotics
SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing...
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
Mikra Announces Joint Product with Jose Bautista
May 06, 2024 07:00 ET
|
Lifeist Wellness Inc.
Lifeist announces FOCUS in partnership with Jose Bautista
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 06, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growth Auvelity® 1Q 2024 net product sales of $53.4 million, representing 240% year-over-year growth Sunosi® 1Q...
Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
May 06, 2024 06:50 ET
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 06, 2024 06:10 ET
|
ADC Therapeutics SA
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $17.8 million in 1Q 2024; total operating expenses decreased 25% (adjusted total operating expenses decreased 16%)1 compared to 1Q 2023 ...
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
May 06, 2024 06:00 ET
|
ADC Therapeutics SA
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All...
AsclepiX Therapeutics Completes Enrollment in DISCOVER Trial for Neovascular Age-Related Macular Degeneration (nAMD)
May 06, 2024 06:00 ET
|
Asclepix
The DISCOVER Phase 1/2a trial is an open-label, single ascending dose, 9-month study that will evaluate the safety and bioactivity of AXT107 (gersizangitide) injected suprachoroidally in patients with...
Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia
May 06, 2024 05:00 ET
|
Boehringer Ingelheim
Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic...
Osteoarthritis Market Forecast Reveals Significant Growth and Upcoming Therapeutic Advancements by 2032
May 06, 2024 04:09 ET
|
Research and Markets
Dublin, May 06, 2024 (GLOBE NEWSWIRE) -- The "Osteoarthritis - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The report...